# QUILT-3.055: what clinicians are saying

> 91 statements from 13 sources (1 podcast, 1 video, 11 posts), 52 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- NCT ID: NCT03228667
- Registry: https://clinicaltrials.gov/study/NCT03228667
- Sponsor: ImmunityBio, Inc.
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: nogapendekin alfa inbakicept (N-803) plus pembrolizumab; nogapendekin alfa inbakicept (N-803) plus pembrolizumab plus PD-L1 t-haNK; nogapendekin alfa inbakicept (N-803) plus pembrolizumab plus docetaxel
- Indication: cancer previously treated with immune checkpoint inhibitors
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: a2824803ceff4d2931dbf777cbdd9cf7ec1573e5bd342913d2d34121903b712e

## Counts

- Commentary sources screened: 26
- Sources cited by verified statements: 13
- Verified statements: 91
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 52
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 9
- Speakers cited: 8
- Cited speakers with a verified identity: 5
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 5
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 5
- By role and specialty (the abstract's specialty counts):
  - 4 physician, specialty not confirmed
  - 1 physician, Hematology and oncology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For QUILT-3.055, a hematology-oncology physician who describes presenting the update and helping develop the approach interprets responses as a signal of renewed checkpoint activity, but another physician wants randomized long-term survival and patient-centered evidence. A physician described in the sources as reporting their own results considers survival observations sufficient for faster access. Anktiva’s contribution beyond continued checkpoint inhibition remains disputed; the ALC–survival association does not prove that lymphocyte restoration causes benefit.

## Question clinicians left open

What randomized evidence on long-term survival and patient-centered outcomes do clinicians say they need before routinely adding N-803 to checkpoint inhibition for NSCLC progressing on checkpoint therapy, as studied in QUILT-3.055?

From finding F1 (11 statements from 4 speakers in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Checkpoint rescue: where clinicians split on readiness for routine use
  - 11 statements from 4 speakers in 2 sources, all podcasts or videos.
  - 3 of the 4 named speakers in this finding take a side on this question: 1 on one side, 2 on the other; every named speaker in this finding is a confirmed clinician.
  - 4 of the report's 5 cited clinicians.
- F2. Nogapendekin alfa inbakicept: why a speaker questions value beyond ICI rechallenge
  - 11 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F3. ALC recovery: where speakers split on what the survival association means
  - 12 statements from 2 speakers in 5 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other.
  - 1 of the report's 5 cited clinicians.
- F4. ALC–survival framing: why a speaker challenges its timing and interpretation
  - 10 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F5. US lung access: where speakers split on approval before phase 3 confirmation
  - 12 statements from 4 speakers in 4 sources, 1 of them a podcast or video.
  - 4 of the 4 named speakers in this finding take a side on this question: 3 on one side, 1 on the other.
  - 3 of the report's 5 cited clinicians.
- F6. QUILT-3.055: what speakers say
  - 9 statements from 2 speakers in 5 sources.
  - No named clinician · accounts and unnamed speakers.
- F7. Side-effect impressions: what clinicians highlight from pooled experience
  - 5 statements from 3 speakers in 1 source, a podcast or video.
  - 3 of the 3 named speakers in this finding hold this view, each a confirmed clinician.
  - 3 of the report's 5 cited clinicians.
- F9. Further trials: where speakers split on confirmation using new ICI combinations
  - 10 statements from 3 speakers in 5 sources, 2 of them podcasts or videos.
  - 3 of the 3 named speakers in this finding take a side on this question: 2 on one side, 1 on the other.
  - 2 of the report's 5 cited clinicians.

### Beyond the trial population

- F8. Immune restoration: clinicians see potential; one needs RCT outcome data
  - 21 statements from 3 speakers in 2 sources, 1 of them a podcast or video.
  - 3 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one needs RCT outcome data”.
  - 3 of the report's 5 cited clinicians.
- F10. Local care: clinicians favor it; one proposes cells with chemo
  - 7 statements from 2 speakers in 1 source, a podcast or video.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one proposes cells with chemo”.
  - 2 of the report's 5 cited clinicians.

2 of the 10 findings and 26 of the 91 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 7 | 2 | 4 | 2 |
| F2 | 11 | 11 | 3 | 1 | 2 |
| F3 | 12 | 11 | 5 | 2 | 3 |
| F4 | 10 | 10 | 2 | 1 | 2 |
| F5 | 12 | 12 | 4 | 4 | 2 |
| F6 | 9 | 7 | 5 | 2 | 3 |
| F7 | 5 | 4 | 1 | 3 | 3 |
| F9 | 10 | 9 | 5 | 3 | 2 |
| F8 | 21 | 14 | 2 | 3 | 3 |
| F10 | 7 | 6 | 1 | 2 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 7 | 1 | 1 | 1 | 1 | 13 | 0 | 2 podcasts and video |
| F2 | 4 | 4 | 0 | 2 | 1 | 13 | 0 | 3 posts and articles |
| F3 | 9 | 1 | 0 | 1 | 1 | 13 | 0 | 4 posts and articles, 1 podcast or video |
| F4 | 7 | 1 | 0 | 0 | 2 | 11 | 0 | 2 posts and articles |
| F5 | 7 | 1 | 0 | 1 | 3 | 14 | 0 | 3 posts and articles, 1 podcast or video |
| F6 | 7 | 0 | 0 | 1 | 1 | 9 | 0 | 5 posts and articles |
| F7 | 3 | 1 | 1 | 0 | 0 | 5 | 0 | 1 podcast or video |
| F9 | 4 | 2 | 2 | 0 | 2 | 12 | 0 | 3 posts and articles, 2 podcasts and video |
| F8 | 11 | 0 | 0 | 3 | 7 | 25 | 2 | 1 post or article, 1 podcast or video |
| F10 | 3 | 0 | 1 | 0 | 3 | 9 | 1 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.: F1 (2 shared claims)
- Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ: F1 (1 shared claims), F2 (3 shared claims), F3 (11 shared claims), F4 (10 shared claims), F6 (4 shared claims)
- Secondary endpoints: F1 (5 shared claims), F2 (3 shared claims), F3 (8 shared claims), F4 (4 shared claims), F6 (5 shared claims), F9 (2 shared claims)
- Population and setting: F1 (6 shared claims), F3 (5 shared claims), F6 (3 shared claims), F9 (2 shared claims)
- The comparison: F1 (2 shared claims), F2 (9 shared claims), F3 (1 shared claims), F4 (1 shared claims), F9 (3 shared claims)
- Safety and tolerability: F2 (2 shared claims), F3 (1 shared claims), F5 (1 shared claims), F6 (1 shared claims), F7 (5 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (4 shared claims), F3 (4 shared claims), F4 (3 shared claims), F6 (1 shared claims), F9 (2 shared claims)

## Abbreviations

- CR: complete response
- HCP: healthcare professional
- ICI: immune checkpoint inhibitor
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- ORR: objective response rate
- OS: overall survival
- PR: partial response
- RCT: randomized controlled trial
- RECIST: Response Evaluation Criteria in Solid Tumors

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 91 | Paid |
| Who said each statement: the cited speakers | 8 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 5 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 5 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 13 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 5 of the 8 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. | discussed | 2 | 1 |
| Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ | discussed | 18 | 7 |
| Secondary endpoints | discussed | 17 | 9 |
| Population and setting | discussed | 11 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 11 | 4 |
| Safety and tolerability | discussed | 8 | 3 |
| Design and conduct | discussed | 10 | 5 |
| Practice readiness, evidentiary sufficiency and access expectations | discussed | 16 | 6 |
| Broader lymphocyte-restoration rationale and proposed supportive-care work-up | discussed | 20 | 2 |
| Confirmatory comparator choices and transfer across combinations | discussed | 9 | 5 |
| Community delivery, research-stage cellular combinations and selective chemotherapy | discussed | 7 | 1 |
| Public interpretation of survival tails, subgroups and anticipated updates | discussed | 9 | 5 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 53 statements · 58%** | | | |
| YouTube | 7 | 1 | 1 |
| Podcasts | 46 | 1 | 1 |
| **Posts · 38 statements · 42%** | | | |
| X threads | 38 | 11 | 24 |

- Screened window: 2017-07-25 to 2026-11-04
- Cited window: 2024-04-26 to 2026-11-04
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Registry: NCT03228667 (https://clinicaltrials.gov/study/NCT03228667)
- Study IDs: CA-ALT-803-02-17
- Sponsor: ImmunityBio, Inc.
- Design: Phase 2 · interventional, non randomized, parallel, phase2
- Status: Active, not recruiting
- Enrollment: 40 (estimated)
- Start: 2018-12-11 (actual)
- Primary completion: 2029-08-31 (estimated)
- Primary endpoint: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. (Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods)
- Primary endpoint: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ (Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes)
- Intervention: N-803 + Pembrolizumab (drug)
- Intervention: N-803 + Nivolumab (drug)
- Intervention: N-803 + Atezolizumab (drug)
- Intervention: N-803 + Avelumab (drug)
- Intervention: N-803 + Durvalumab (drug)
- Intervention: N-803 + Pembrolizumab + PD-L1 t-haNK (drug)
- Intervention: N-803 + Nivolumab + PD-L1 t-haNK (drug)
- Intervention: N-803 + Atezolizumab + PD-L1 t-haNK (drug)
- Intervention: N-803 + Avelumab + PD-L1 t-haNK (drug)
- Intervention: N-803 + Durvalumab + PD-L1 t-haNK (drug)
- Intervention: N-803 + Docetaxel + Pembrolizumab (drug)
- Intervention: N-803 + Docetaxel + Nivolumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 57 sources about other trials or topics are not included; 37 sources that may describe the trial without naming it were not read.
- The sources reviewed for this edition do not represent all HCPs or establish how common any view is; repeated posts and source totals are not independent clinician counts.
- Potentially relevant discussion that did not name the trial was not all read. Unnamed references and alternative transcriptions may therefore be missing.
- No full protocol or exact-trial results publication was found among the sources reviewed. Descriptions of peer-review submission do not establish completed publication.
- Clinical roles are not established for several named or pseudonymous X accounts. Their statements are distinguished from clinician interviews and organizational commentary.
- Some remarks on the Oncology Brothers episode cannot be assigned to a named speaker and cannot be counted as additional independent agreement or disagreement.
- Survival figures refer to differing cohort descriptions, biomarker thresholds and analysis dates. They cannot be treated as interchangeable estimates or pooled into a comparative effect.
- The detailed safety account concerns pooled exposure rather than a QUILT-3.055 adverse-event table; favorable impressions do not establish absence of other toxicity or comparative safety.
- Exact combination labels, reimbursement decisions and the regulatory allegations discussed by accounts were not established by the sources reviewed.
- Later descriptions of confirmatory regimens and comparators differ. They do not establish that all proposed studies test the same combination or isolate the same component effect.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-20 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 91 verified statements · 52 from 5 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (5 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/quilt-3-055-nct03228667
- Agents: POST https://www.erudio.com/api/orders with {"report": "quilt-3-055-nct03228667", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=quilt-3-055-nct03228667

## Cite

Erudio Health. QUILT-3.055 (NCT03228667): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/quilt-3-055-nct03228667

## Questions

### How much does the QUILT-3.055 report cost?

One edition costs $750 (Focused · 91 verified statements · 52 from 5 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the QUILT-3.055 report cover?

91 statements from 13 sources (1 podcast, 1 video, 11 posts), 52 of them from 5 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the QUILT-3.055 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "quilt-3-055-nct03228667" }) previews it and create_order({ "report": "quilt-3-055-nct03228667", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the QUILT-3.055 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/quilt-3-055-nct03228667.json
- Markdown: https://www.erudio.com/reports/quilt-3-055-nct03228667.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/quilt-3-055-nct03228667/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "quilt-3-055-nct03228667"}`
